Summary & Overview
HCPCS J9281: Mitomycin Pyelocalyceal Instillation, 1 mg
HCPCS Level II code J9281 represents mitomycin pyelocalyceal instillation, 1 mg — a localized chemotherapy administration used in urologic care for instillation into the renal pelvis and calyces. Nationally, this code matters because it captures a specialized drug administration procedure distinct from systemic chemotherapy and has implications for site-of-service billing, drug preparation and waste reporting, and clinical documentation for upper urinary tract disease management. Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Readers will gain: a concise explanation of what the code denotes clinically; payer coverage context and common billing considerations; benchmark and payment context where available; and relevant clinical and administrative touchpoints for documenting and coding this instillation procedure. The publication covers national policy and reimbursement themes affecting this HCPCS Level II medication code, including how the designation as an HCPCS Level II drug code informs billing pathways and typical settings for service delivery. Data not available in the input will be noted where applicable.
Billing Code Overview
HCPCS Level II code J9281 describes mitomycin pyelocalyceal instillation, 1 mg. This service involves the direct instillation of mitomycin into the pyelocalyceal system, a localized chemotherapy delivery intended for urologic management within the upper urinary tract. The service type is a medication administration procedure for intraluminal chemotherapy. The typical site of service is a hospital outpatient department or an ambulatory surgery center where urologic endoscopic procedures and localized chemotherapeutic instillations are performed.
Clinical & Coding Specifications
Clinical Context
A typical patient is a 60-year-old with a history of recurrent non-muscle invasive urothelial carcinoma of the renal pelvis or upper urinary tract who presents for intrarenal instillation of mitomycin to reduce recurrence risk after endoscopic tumor ablation. The patient arrives to an outpatient ambulatory surgery center or hospital outpatient department after pre-procedure evaluation confirming adequate renal function and no active infection. Under fluoroscopic or endoscopic guidance, a urologist accesses the renal collecting system via a percutaneous nephrostomy tube or a retrograde ureteral catheter. Mitomycin, supplied and billed per milligram with J9281 representing mitomycin pyelocalyceal instillation, 1 mg, is instilled into the renal pelvis and calyces and retained for a prescribed dwell time before drainage. The workflow includes medication preparation by pharmacy, sterile instillation by the procedural team, monitoring for immediate adverse reactions, and post-procedure instructions for urine precautions and symptom monitoring. Typical site of service is an ambulatory surgery center, hospital outpatient department, or interventional radiology suite; the procedure is performed by a urologist or interventional radiologist familiar with upper-tract intraluminal chemotherapy administration.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier | Use when no other modifier applies and full global service is reported. |